CAPTRUST Financial Advisors
SCPS

CAPTRUST Financial Advisors’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SCPS Stock Details SCPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-95
Closed -$1K – 4853
2021
Q2 		$1K Buy
+95
New +$676 ﹤0.01% 4432

Other funds holding SCPS

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAPTRUST Financial Advisors's SCPS Position: Q3 2021 in Review

CAPTRUST Financial Advisors sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q3 2021, closing a stake of 95 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in SCPS in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 14 funds tracked by Wall St. Rank hold SCPS as of Q3 2021.

  • CAPTRUST Financial Advisors reported no remaining Scopus BioPharma Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 95 Scopus BioPharma Inc. Common Stock shares in Q3 2021, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Scopus BioPharma Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Scopus BioPharma Inc. Common Stock position peaked at $1K in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q3 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.